Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles B Malpas

Showing results (81-90 of 141) with videos related to

Pageof 15
Sort By:
Journal of Neurology|June 25, 2024
Memory function in autoimmune encephalitis: a cross-sectional prospective study utilising multiple memory paradigmsSarah P Griffith, Robb Wesselingh, Nabil Seery, et al.
BMJ Open|November 17, 2020
A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementiaLucy Vivash, Charles B Malpas, Leonid Churilov, et al.
Internal Medicine Journal|October 31, 2022
Cerebrospinal fluid neurofilament light and cerebral atrophy in younger-onset dementia and primary psychiatric disordersNirbaanjot Walia, Dhamidhu Eratne, Samantha M Loi, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|February 15, 2024
Language impairments in seropositive and seronegative autoimmune encephalitisSarah P Griffith, Robb Wesselingh, Fiore D'Aprano, et al.
Expert Review of Hematology|August 1, 2025
Cognitive impairment in hematology patients planned for chimeric antigen receptor T-cell therapyValeriya Kuznetsova, Hannah Rosenfeld, Carmela Sales, et al.
Epilepsy & Behavior : E&B|December 28, 2020
Adverse events related to antiepileptic drugsYew Li Dang, Emma Foster, Michael Lloyd, et al.
The Australian and New Zealand Journal of Psychiatry|June 22, 2019
A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A 'C-reactive protein' for psychiatrists and neurologists?Dhamidhu Eratne, Samantha M Loi, Nirbaanjot Walia, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 30, 2025
Plasma p-tau217, NfL, GFAP diagnostic performance and biomarker profiles in Alzheimer's disease, frontotemporal dementia, and psychiatric disorders, in a prospective unselected neuropsychiatry memory clinicDhamidhu Eratne, Matthew Kang, Charles B Malpas, et al.
Alzheimer'S & Dementia (New York, N. Y.)|May 16, 2022
A phase 1b open-label study of sodium selenate as a disease-modifying treatment for possible behavioral variant frontotemporal dementiaLucy Vivash, Charles B Malpas, Christian Meletis, et al.
Journal of Alzheimer'S Disease : JAD|July 23, 2016
A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's DiseaseCharles B Malpas, Lucy Vivash, Sila Genc, et al.
Pageof 15

Showing results (81-90 of 141) with videos related to

Sort By:
Pageof 15
Journal of Neurology|June 25, 2024
Memory function in autoimmune encephalitis: a cross-sectional prospective study utilising multiple memory paradigmsSarah P Griffith, Robb Wesselingh, Nabil Seery, et al.
BMJ Open|November 17, 2020
A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementiaLucy Vivash, Charles B Malpas, Leonid Churilov, et al.
Internal Medicine Journal|October 31, 2022
Cerebrospinal fluid neurofilament light and cerebral atrophy in younger-onset dementia and primary psychiatric disordersNirbaanjot Walia, Dhamidhu Eratne, Samantha M Loi, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|February 15, 2024
Language impairments in seropositive and seronegative autoimmune encephalitisSarah P Griffith, Robb Wesselingh, Fiore D'Aprano, et al.
Expert Review of Hematology|August 1, 2025
Cognitive impairment in hematology patients planned for chimeric antigen receptor T-cell therapyValeriya Kuznetsova, Hannah Rosenfeld, Carmela Sales, et al.
Epilepsy & Behavior : E&B|December 28, 2020
Adverse events related to antiepileptic drugsYew Li Dang, Emma Foster, Michael Lloyd, et al.
The Australian and New Zealand Journal of Psychiatry|June 22, 2019
A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A 'C-reactive protein' for psychiatrists and neurologists?Dhamidhu Eratne, Samantha M Loi, Nirbaanjot Walia, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 30, 2025
Plasma p-tau217, NfL, GFAP diagnostic performance and biomarker profiles in Alzheimer's disease, frontotemporal dementia, and psychiatric disorders, in a prospective unselected neuropsychiatry memory clinicDhamidhu Eratne, Matthew Kang, Charles B Malpas, et al.
Alzheimer'S & Dementia (New York, N. Y.)|May 16, 2022
A phase 1b open-label study of sodium selenate as a disease-modifying treatment for possible behavioral variant frontotemporal dementiaLucy Vivash, Charles B Malpas, Christian Meletis, et al.
Journal of Alzheimer'S Disease : JAD|July 23, 2016
A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's DiseaseCharles B Malpas, Lucy Vivash, Sila Genc, et al.
Pageof 15